AD/PD 2024 | Metabolome-wide association studies in Alzheimer’s disease

Genome-wide association studies (GWAS) in Alzheimer’s disease (AD) have identified many risk loci, however the mechanisms by which these confer susceptibility to AD are poorly understood. Rui Pinto, PhD, Imperial College London, London, UK, discusses results from a metabolome-wide association study (MWAS) to detect metabolic features associated with genetic variants for AD, which revealed that AD-related single-nucleotide polymorphisms in ABCA7 were associated with lactosylceramides. Notably, plasma lactosylceramide concentrations were associated with cognitive performance. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.